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The proin¯ammatory cytokine interleukin-12, a p35/
p40 heterodimer, is produced by resident cells in
skin and has been implicated as a pathogenetic factor
in T-cell-mediated skin diseases. Secretion of hetero-
dimeric interleukin-12 is always accompanied by
production of p40 monomer and p40/p40 homodi-
mer. To investigate the possible in vivo role of p40
per se, we generated mice that constitutively express
monomeric and homodimeric p40 in basal keratino-
cytes. These mice spontaneously developed an ecze-
matous skin disease that was characterized by
hyperkeratosis, focal epidermal spongiosis, and a
mixed in¯ammatory in®ltrate composed of T cells
(CD4+), macrophages, eosinophils, mast cells, and
few neutrophils. Fluorescence-activated cell sorter
analysis of transgenic epidermal cell suspensions
revealed induction of major histocompatibility com-
plex class II molecules on keratinocytes and a 2±3-
fold increase in the content of Langerhans cells.
Cytokines produced by these activated epidermal
cells include interleukin-1a and tumor necrosis fac-
tor a. The skin disease in K14/p40 mice was similar
to that of littermate mice that received injections of
interleukin-12, suggesting overlapping in vivo func-
tional properties. As induction of interferon-g is a
major function of interleukin-12, we tested the in vitro
ability of transgenic p40 to induce interferon-g. In
contrast to interleukin-12, transgenic p40 did not
stimulate interferon-g secretion by cultured spleno-
cytes. We conclude that transgenic p40 and interleu-
kin-12 are equally capable of initiating cutaneous
in¯ammation. Despite these in vivo similarities, there
is a clear functional difference between interleukin-
12 and transgenic p40 in vitro, suggesting that inter-
feron-g is not a major factor contributing to interleu-
kin-12-like activities of transgenic p40. Key words:
animals/cytokines/eczema/inbred FVB/mice/skin immu-
nostaining. J Invest Dermatol 117:618±626, 2001
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nterleukin-12 (IL-12) is an immunoregulatory cytokine that
promotes cell-mediated immunity. Besides its capacity to
augment CTL and natural killer cell activity, IL-12 commits
differentiation of naive CD4 and CD8 T cells to cells that
preferentially produce interferon-g (IFN-g) and interleukin-
2 (IL-2) (Trinchieri, 1995; Gately et al, 1998). The importance of
IL-12 in vivo has been demonstrated using IL-12 antagonists, which
suppress Th1-associated autoimmune responses such as experi-
mental allergic encephalomyelitis, insulin-dependent diabetes
mellitus, and in¯ammatory bowel disease (Leonard et al, 1995;
Neurath et al, 1995; Trembleau et al, 1997), and recombinant IL-
12, which inhibits allergen-induced airway hyperreactivity and
eosinophil accumulation in the lung in Th2-mediated murine
models of allergic asthma (Gavett et al, 1995; Kips et al, 1996).
IL-12 p35 and p40 mRNA as well as p40 and p70 protein are
inducible in resident skin cells including Langerhans cells and
human keratinocytes (MuÈller et al, 1994; Heu¯er et al, 1996;
Yawalkar et al, 1996). Participation of endogenous IL-12 p70 and
p40 in pathophysiologic processes relevant to cutaneous in¯am-
mation has been suggested by increased IL-12 p40 mRNA
expression in atopy patch test sites as well as IL-12 p40 mRNA
and IL-12 p70 protein expression in psoriatic skin (Junghans et al,
1998; Yawalkar et al, 1998). In addition, a pivotal role for IL-12
p70 in the induction of contact hypersensitivity was demonstrated
in blocking experiments using an anti-p40 antibody as well as an
anti-IL-12 antiserum. This resulted in inhibition of sensitization
and induction of hapten-speci®c tolerance (MuÈller et al, 1995b;
Riemann et al, 1996).
IL-12 p70 is a heterodimeric protein consisting of two covalently
linked chains, p35 and p40 (Wolf et al, 1994; Trinchieri, 1995).
Both subunits expressed by one cell are required for IL-12
bioactivity. The biologic activities of IL-12 are mediated by the
high af®nity IL-12 receptor (IL-12R), which is composed of the
IL-12R b1 and the IL-12R b2 chains (Presky et al, 1996). Studies
investigating the tissue distribution of the high af®nity IL-12R have
shown its presence primarily on natural killer cells and T cells
(Thibodeaux et al, 1999; Wu et al, 2000). There also exist reports
demonstrating IL-12R b expression on B cells and melanoma cells,
however (Thibodeaux et al, 1999; Yue et al, 1999).
In contrast to p35, which is constitutively expressed on many cell
types, p40 is inducible in dendritic cells, macrophages, and
keratinocytes by a variety of stimuli (MuÈller et al, 1995a; Heu¯er
et al, 1996). Cells that are able to secrete heterodimeric IL-12
always produce an excess of the free p40 subunit (D'Andrea et al,
1992; Podlaski et al, 1992). Whereas the biologic effects of IL-12
p70 are well studied, the physiologic signi®cance of IL-12 p40
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remains controversial. For example, it has been demonstrated that
p40 homodimer and, to a lesser degree, P40 monomer antagonize
IL-12 bioactivity by binding to the IL-12R b1 without delivering a
signal (Ling et al, 1995; Gately et al, 1996). Despite its potent IL-12
antagonistic function in many systems, endogenous p40 was
reported to act as an IL-12 agonist in certain situations (Decken
et al, 1998; Piccotti et al, 1998).
Although it is attractive to speculate about the role of IL-12 p40
in skin in¯ammation, experimental systems designed to test this
hypothesis are missing. In this study we evaluate whether the local
presence of endogenous IL-12 p40 in skin is a cause or a
consequence of cutaneous in¯ammation. Using a keratinocyte-
speci®c keratin promoter (K14), we have made mice that
constitutively express IL-12 p40 in the basal layer of the epidermis
but, at the same time, do not produce detectable amounts of
biologically active epidermal IL-12. Our results show that p40
single transgenic mice exhibit skin changes identical to those seen
in mice injected with recombinant IL-12. To our knowledge, these
results are the ®rst that demonstrate that IL-12 p40, produced in vivo
by basal keratinocytes, results in a spontaneous in¯ammatory skin
phenotype.
MATERIALS AND METHODS
DNA construct and transgenic mice A cDNA comprising the entire
coding region of murine p40 (1035 bp) (the kind gift of Dr. M. Gately,
Hoffman LaRoche, Nutley, NJ) was inserted into the Bam HI site of the
K14/hGH expression vector (a kind gift of Prof. E. Fuchs, University of
Chicago, Chicago, IL) by blunt end ligation. The resulting plasmid was
digested with EcoRI to generate the 5.285 kb K14/p40/hGH fragment
(Fig 1) that was used for microinjection of fertilized ova of FVB/N
mice (Taconic, Germantown, NY). Transgenic founders were identi®ed
by polymerase chain reaction (PCR) and by southern blot analysis and
bred to establish lines. All animals were bred under pathogen-free
conditions and used for experiments at 6±12 wk of age.
RNA analysis For reverse transcriptase PCR (RT-PCR) total RNA
was prepared from cultured basal transgenic and control keratinocytes
and from phorbol 12-myristate 13-acetate (PMA) stimulated spleen cells
using the RNEASy Minikit from Qiagen (Valencia, CA). One
microgram of total RNA was reverse transcribed using the Superscript
First Strand Synthesis System for RT-PCR from GibcoBRL (Life
Technologies, Gaithersburg, MD). Two microliters of the reverse
transcriptase reaction was ampli®ed using primers speci®c for murine p35
and b-actin. For both primers published sequences were used (Tokunaga
Figure 1. Characterisation of the transgenic
product at the protein and RNA level.
(A) K14/p40/hGH construct used for micro-
injection of fertilized ova. Murine p40 cDNA was
inserted at the BamH1 site of the K14/hGH
expression vector by blunt end ligation. (B) IL-12
p40 is expressed in the basal layer of epidermis in
p40 transgenic mice. A frozen section of ear skin
from p40 mice was stained for p40 with C17.8
MoAb (magni®cation, 3115). (C) P35 mRNA is
not expressed by basal murine keratinocytes.
RNA was extracted from 3 d cultured basal
transgenic and littermate keratinocytes and RT-
PCR for p35 and b-actin was performed as
described in Materials and Methods. Lane 1, K14/
p35/hGH construct (positive control 1); lane 2,
RNA isolated from CON-A-stimulated spleno-
cytes (positive control 2); lane 3, RNA isolated
from transgenic keratinocytes; lane 4, RNA
isolated from littermate keratinocytes.
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et al, 1986; Piccotti et al, 1996; Khiri et al, 1996). For PCR
ampli®cation, 50 ml of reaction containing 1 ml cDNA, 200 mM dNTP
(each), 20 pmol of each primer, and the standard buffer supplemented
with Platinum Taq polymerase (2.5 U per reaction; GibcoBRL) and
1.5 mM MgCl2 were used. Primer sequences and product sizes were as
follows: P35 sense, 5¢-ACCAGCACATTGAAGACCTG-3¢; P35 anti-
sense, 5¢-GACTGCATCAGCTCATCGAT-3¢, 272 bp; b-actin sense,
5¢-GTCGTACCACAGGCATTGTGATTG-3¢; b-actin antisense,
5¢-GCAATGCCTGGGTACATGGTGG-3¢, 490 bp. Samples were
ampli®ed in a thermal cycler (Perkin Elmer, Foster City, CA) with an
initial 3 min denaturation step followed by 35 cycles of 94°C, 56°C, and
72°C, all for 1 min. PCR products were separated at 120 V in a 1.5%
agarose gel. PMA-stimulated splenocytes and the K14/p35/hGH vector
served as a positive control for p35. Ampli®cation of b-actin veri®ed the
presence of cDNA.
For northern blot analysis total RNA was isolated from various tissues
of transgenic and littermate mice by TRI reagent (Molecular Research
Center, Cincinnati, OH). Ten micrograms of total RNA were size
fractionated by gel electrophoresis on a 1% formaldehyde/agarose gel.
RNA was transferred to a nylon membrane (Hybond N+ Amersham
Pharmacia Biotech, Piscataway, NJ) and hybridized with P32-labeled
cDNA for murine p40. After hybridization blots were washed twice at
65°C in 1 3 standard saline citrate (SSC)/0.1% sodium dodecyl sulfate
(SDS), and twice in 0.1 3 SSC/0.1% SDS. Blots were then exposed to
X-ray ®lm at ±70°C.





per ml p40% p40/p40%
Plasma
P40.1 11 31.00 6 15 0 ± ±
P40.10 3 9.26 1.23 0 ± ±
LM 3 2.28 0.11 0 ± ±
P40.1 pool 4 32 0 52 48
P40.10 pool 5 8.04 0 69 31
Medium
Kc p40.1 8 38.01 10.6 0 ± ±
Kc Lm 8 0 0 ± ±
Kc p40.1 pool 5 36.2 0 57 43
Kc p40.10 pool 5 14.04 0 72 28
Con A stim. splenocytes ± 36.5 ± ±
aTransgenic keratinocytes secrete p40 and p40/p40 but no heterodimeric IL-12.
Immunoreactive p40 and p35/p40 protein in media conditioned by transgenic and
control keratinocytes and in plasma from transgenic and control mice were mea-
sured by ELISA. The relative content of p40 and p40/p40 in total p40 immunor-
eactivity was determined by fractionating the samples by size exclusion
chromatography followed by measuring individual fractions by ELISA.
Figure 2. P40 transgenic mice exhibit a
spontaneous macroscopic and microscopic
phenotype. (A) 5-d-old littermate and p40
transgenic mice. Note the scales on the back of
the transgenic mice. (D) 10-wk-old littermate
mouse. (H) In¯ammatory skin lesions located on
the ears, the back, and the face of a 10-wk-old
homozygous mouse. (F) Less affected
heterozygous p40 transgenic mouse. (B, C, E, G,
I) Histologic evaluation of sections from the back
skin of transgenic and littermate mice. A subtle
epidermal thickening is visible in 5-d-old
transgenic mice (B) compared to littermate
controls (C) (magni®cation, 360). Epidermal
thickening, focal intraepithelial edema, and
in¯ammatory in®ltrate in skin sections of
heterozygous (G) and homozygous (I) mice. (E)
Back skin from a littermate mouse. (E, G, I:
magni®cation, 3140).
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Cytokines, cytokine assay systems, and epidermal cell
culture Epidermal cell suspensions were obtained by sequential dispase
and trypsin digestion of split mouse ears as previously described
(Rauschmayr et al, 1997). Keratinocytes thus obtained were cultured on
collagen-coated plates, using non-differentiating conditions, with
medium containing 0.05 mM Ca2+ to allow maintenance of K14
expression. After 48 h of culture immunoreactive cytokines secreted into
the supernatant were quantitated by enzyme-linked immunosorbent assay
(ELISA).
Murine IL-12 p40 was assayed using the p40 ELISA according to the
manufacturer's instructions (Pharmingen, San Diego, CA). ELISA
reagents for detection of IL-12 p70 were a kind gift of Dr. Presky,
Hoffman LaRoche, Nutley, NJ. In contrast to the p40 ELISA, which is
reactive with all IL-12 proteins (p40, p40/p40, and p35/p40), the p70
ELISA exclusively detects heterodimeric IL-12 (p35/p40). The IL-12
p70 assay was performed as originally described (Wilkinson et al, 1996).
Brie¯y, ¯at bottom 96-well plates (Costar, Cambridge, MA) were coated
with rat anti-mouse IL-12 p70 monoclonal antibody (MoAb) (9A5).
Immunoreactive IL-12 p70 was detected using a peroxidase-labeled rat
antimouse IL-12 p40 MoAb (5C3) and the appropriate substrate system.
Samples were also analyzed with the highly sensitive Quantikine M
mouse IL-12 p70 immunoassay from R&D (Minneapolis, MN). IL-1a
and tumor necrosis factor a (TNF-a) secreted by transgenic and control
keratinocytes were measured using ELISA kits from Endogen and
Genzyme (Woburn and Cambridge, MA).
Column chromatography To determine the relative content of p40
and p40/40 in media conditioned by transgenic keratinocytes and plasma
of transgenic mice, the samples were fractionated by size exclusion
chromatography, and the p40 immunoreactivity of individual fractions
was assessed. A calibrated size exclusion column (83 3 1.5 cm) of
Sephadex G100 (Amersham Pharmacia), eluted with phosphate-buffered
saline (PBS), was employed.
Histology and immunostaining Hematoxylin and eosin stainings
were performed by standard methods. Eosinophils were stained with
Biebrich red according to Luna's method and mast cells were visualized
using a conventional chloroacetate esterase stain (Leder, 1979).
Antibodies for immunostaining Monoclonal antibodies puri®ed from
hybridoma supernatants were purchased from ATCC [M5-114.15.2 (anti
I-Ab,d,q and I-Ed,k, TIB 120), GK1.5 (anti CD4, TIB 207), F4/80
(macrophage)] or from Serotec [Oxford, U.K.: NLDC-145 (anti-DEC-
205)]. The MoAb RB6-8C5 (Gr-1) and ¯uorescein isothiocyanate
(FITC) 30F11.1 (anti-CD45) were obtained from Pharmingen and the
phycoerythrin-conjugated MoAb M5-114.15.2 (anti I-Ab,d,q and I-Ed,k)
from Boehringer Mannheim (Vienna, Austria). Secondary antibodies, the
biotinylated sheep anti-rat Ig (polyclonal) and the biotinylated goat anti-
hamster Ig (polyclonal), were purchased from Amersham (Arlington
Heights, IL) and Medac (Hamburg, Germany), respectively. FITC-
labeled goat anti-rat Ig (polyclonal) was obtained from Pharmingen.
Control antibodies used included irrelevant isotype-matched MoAb, rat
or hamster IgG, from Pharmingen.
Immuno¯uorescence staining Ear skin and back skin biopsies from
transgenic and control mice were embedded in Tissue-Tec II (Miles,
Elkhart, IN) and frozen in isopentane precooled in liquid nitrogen.
Cryostat sections (5 mm) were ®xed for 10 min in acetone at 4°C and
subjected to immunostaining. Brie¯y, sections were incubated overnight
at 4°C with the indicated primary antibodies appropriately diluted in
PBS. Following washing, antibody binding was visualized by further
incubation with the indicated biotinylated secondary antibody and,
subsequently, with Texas-Red-labeled streptavidin (Amersham) for 1 h at
room temperature.
Immunoperoxidase staining Cryostat sections were ®xed in acetone (4°C)
for 10 min. After washing with PBS, sections were incubated overnight
with the respective MoAb appropriately diluted in PBS. For detection of
p40, cryostat sections were ®xed in 4% paraformaldehyde in PBS
followed by washing with PBS containing 0.1% saponin, and
immunostaining was performed as previously described (Gorak et al,
1998). Brie¯y, sections were incubated at room temperature with rat
anti-mouse p40 antibody C17.8 (Pharmingen) appropriately diluted in
Figure 3. Identi®cation of the in¯ammatory in®ltrate in the skin of K14/p40 transgenic mice by immunophenotyping. Frozen ear skin
sections from littermate (right panel) and heterozygous p40 transgenic mice (left panel) were stained for CD4 (A, B), DEC 205 (C, D), F4/80 (E, F),
MHC class II (G, H), and Gr-1 (I, J) as indicated. Chloroacetate esterase (K, L) and Biebrich (M, N) staining. (A±L, N: magni®cation, 370;
M: magni®cation, 3250).
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PBS. Primary antibody binding was revealed using the indicated
biotinylated second step antibody and the StreptABComplex (Dako,
Carpinteria, CA). Sections were developed in 3-amino-9-ethylcarbazole
(Sigma, Vienna, Austria), counterstained with Harris's hematoxylin
(Merck, West Point, PA), and mounted.
Subcutaneous injection of cytokines and ¯ow
cytometry Transgenic and littermate control mice (four to ®ve mice
per group) were injected subcutaneously into the right ear with either
recombinant IL-12 (100 ng), p40/40 (1 mg), or vehicle (PBS + 1%
bovine serum albumin) alone in a total volume of 50 ml every other day
for two consecutive weeks. Ear thickness was measured before and at
multiple time points after injection with an engineer's caliper (Hahn und
Kolb, Stuttgart, Germany). After 2 wk epidermal cell suspensions were
prepared from mouse ears by sequential dispase and trypsin treatment.
For two-color analyses cells were incubated with FITC-conjugated
MoAb against CD45 (30F11, Pharmingen) and phycoerythrin-conjugated
anti-major histocompatibility complex (MHC) class II MoAb (M5/
114.15.2, Boehringer Mannheim).
IL-12 antibody capture bioassay The IL-12 bioassay was performed
as previously described (Wysocka et al, 1995). After coating the 96-well
culture plates with the nonblocking anti-p40 antibody C15.1 (20 mg per
ml, Pharmingen), murine recombinant IL-12 (several dilutions),
recombinant p40/p40 (12.5±200 ng per ml), and the experimental
samples (media conditioned by transgenic keratinocytes or littermate
keratinocytes) were added to the plates and incubated for 5 h. After
washing with PBS, littermate splenocytes (5 3 105) were added. IFN-g
secretion was assayed after 48 h by ELISA according to the
manufacturer's instructions (Pharmingen). A potential IL-12-inhibitory
effect of transgenic p40 was tested in some experiments. Here, media
conditioned by K14/p40 transgenic or control keratinocytes were added
to IL-12-stimulated splenocytes. As a control, we added either p40/40
(200 ng per ml) or the blocking antibody Sheep7 (1.5 mg per ml), a kind
gift of Dr. Stanley Wolf from the Genetics Institute (Boston, MA).
RESULTS
Generation of K14/p40 transgenic mice Transgenic mice
were generated using the construct shown in Fig 1(A). The mouse
cDNA for p40 was cloned into the K14/hGH vector described
previously. Two transgenic founders, which transmitted the
transgene to their offspring, were identi®ed by PCR and
southern blot analysis. Thus, we obtained two heterozygous lines
designated K14/p40.1 and K14/p40.10 with an estimated
copynumber of integrated transgene of 40 and 5, respectively.
Northern blot analysis of ear skin from K14/p40.1 and K14.p40.10
mice demonstrated tissue-speci®c transgene mRNA expression
(data not shown). We also obtained homozygous mice, but due to
their reduced breeding behavior we could not establish lines from
these mice. All experiments were performed with age- and sex-
matched heterozygous K14/p40.1 and littermate mice.
Keratinocytes from K14/p40 mice secrete p40 and p40/40
but no heterodimeric (p35/p40) IL-12 High level transgene
expression in basal keratinocytes was demonstrated by immuno-
histochemical analysis of ear skin sections stained with the anti-mu
IL-12 p40 MoAb (C17.8) (Fig 1B). No immunoreactivity was
observed in control animals (data not shown).
A speci®c ELISA for mouse p40 established transgenic protein
secretion by K14/p40 keratinocytes. Medium conditioned by
transgenic keratinocytes and plasma from transgenic mice contained
36.2 ng per ml and 32 ng per ml of total immunoreactive p40 in
K14/p40.1, and 14.04 ng per ml and 8.04 ng per ml in K14/
p40.10 mice, respectively. As p40 exists in two forms, i.e., as a
monomer and as a homodimer, we investigated whether K14/p40
transgenic keratinocytes can secrete either of these. Medium and
plasma proteins were fractionated by size and the amount of p40 in
individual fractions was measured by ELISA. Speci®c total
immunoreactivity in medium comprised 57% p40 and 43% p40/
40 in the p40.1 line and 72% p40 and 28% p40/40 in the p40.10
line. Plasma from K14/p40.1 mice contained 52% p40 and 48%
p40/40 and plasma from K14/p40.10 mice 69% p40 and 31% p40/
40. No heterodimeric IL-12 could be detected by ELISA in either
line (Table I). To investigate whether the lack of heterodimeric
IL-12 was a result of missing p35 mRNA expression, RT-PCR for
p35 was performed in littermate and transgenic keratinocytes. In
contrast to PMA-stimulated splenocytes, which served as a positive
control, no p35 mRNA was detectable in either littermate or
transgenic basal keratinocytes (Fig 1C). Thus, the absence of
heterodimeric IL-12 protein measured by ELISA can be explained
by the complete lack of p35 mRNA.
K14/p40 mice spontaneously develop an in¯ammatory skin
disease Contrary to what we had expected, mice from both
K14/p40 lines consistently displayed a striking in¯ammatory skin
disease. At birth, K14/p40 mice were indistinguishable from
nontransgenic littermates. At the age of 5 d, just before the ®rst hair
was visible, transgenic mice developed loose scales localized on the
entire body including paws and tail (Fig 2A). The skin disease
progressed spontaneously. Adult mice exhibited an in¯ammatory
skin disease with skin lesions most prominent on and behind the
ears, on the face, and on the back (Fig 2F, H). The most severely
affected animals were essentially erythrodermic and some of them
developed a wasting syndrome. Clinically, the skin phenotype was
characterized by erythema, erosions, crusts, hair loss, and skin
thickening. We also observed frequent scratchmarks in K14/p40
mice suggesting that transgenic mice suffer from pruritus.
Homozygous mice (Fig 2H) were more severely affected than
heterozygous mice (Fig 2F).
Histologic evaluation and immunophenotyping of skin
from K14/p40 mice In order to identify early histologic
changes, sections were taken from transgenic and littermate back
skin of 5-d-old mice (Fig 2A). Histologic evaluation revealed
subtle thickening of the transgenic epidermis (Fig 2B) compared to
age-matched littermate control skin (Fig 2C). In both transgenic
and littermate mice, the dermis was dominated by long hair follicles
Figure 4. K14/p40 mice have thicker ears than control
littermates and contain increased numbers of Langerhans cells.
(A) Ear thickness in littermate and p40 transgenic mice. Data are
presented as the mean ear thickness 6 SD of ®ve mice per group. (B)
FACS analysis of epidermal cell suspensions from littermate and p40
transgenic mice. Freshly isolated epidermal cell suspensions were
incubated with FITC-labeled MoAb directed against CD45 and PE-
labeled MoAb against MHC class II.
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typical of the anagen phase of the hair cycle with a slight increase in
dermal cellularity in K14/p40 mice. Adult mouse skin from
different anatomic locations was characterized by various grades
of epidermal thickening, focal intraepithelial edema, and a
mononuclear in®ltrate (Fig 2G, I). The dermal compartment
typically contained increased numbers of in¯ammatory cells
(Fig 2G, I) consisting of T cells (CD4+) (Fig 3A), macrophages
(F4/80) (Fig 3E), and few granulocytes (Gr-1+) (Fig 3I). CD4+
lymphocytes were also localized in transgenic epidermis (Fig 3A).
In addition, we observed increased numbers of eosinophils
(Fig 3M) and mast cells (Fig 3K) in K14/p40-derived lesional
skin. Interestingly, CD8+ T cells were not part of the in®ltrate.
Transgenic mice contained more MHC-class-II- and DEC-205-
expressing cells (i.e., dendritic cells) in both the epidermal and the
dermal compartment (Fig 3C, G) than control animals and
displayed MHC class II not only on dendritic cells but also on
keratinocytes (Fig 3G). In contrast to these profound alterations in
skin morphology, other organs such as heart, lung, liver, kidney,
and pancreas appeared normal.
Subcutaneous injections of IL-12 cause a skin disease similar
to that of K14/p40 transgenic mice The in¯ammatory skin
disease in K14/p40 mice is paralleled by increased ear thickness.
Compared to the ear thickness of littermate mice at an age of 10 wk
(225 mm 6 5.7), transgenic ears measure 296.25 mm 6 17.9 (see
Fig 4A). Fluorescence-activated cell sorter (FACS) analysis of
transgenic epidermal cell suspensions typically reveals induction of
MHC class II molecules on keratinocytes and a 2±3-fold increase in
the content of Langerhans cells (see Fig 4B). In order to imitate the
situation in K14/p40 mice in a different experimental approach, we
subcutaneously injected recombinant IL-12, p40/40, or vehicle
alone every other day in the ears of non-transgenic littermates for a
period of two consecutive weeks. We found that injections of
IL-12 resulted in a skin phenotype comparable to that of K14/p40
mice. Similar to the spontaneous ear thickening in K14/p40 mice,
we observed an ear swelling response in littermate mice upon
repeated injections of recombinant IL-12 (Fig 5A). In addition,
cellular characteristics such as MHC class II surface expression on
keratinocytes and a higher number of epidermal Langerhans cells
were identical to our ®ndings in K14/p40 mice (Fig 5B.A). In
contrast, injections of p40/40 or vehicle alone did not alter ear
thickness (Fig 5A) and the FACS pro®le (Fig 5B.C and 5B.E) of
epidermal cells compared to uninjected littermates (Fig 4A, B). In
K14/p40 mice, the extent of IL-12-induced ear swelling was
comparable to that in IL-12-injected littermates (Fig 5A).
Injections of p40/40 had no in¯uence on ear thickness and on
the epidermal phenotype of K14/p40 mice. These results speak for
an IL-12-like activity of transgenic p40 in K14/p40 mice. The
reason for the discrepancy between the effect of exogenously
injected p40/40 and endogenous p40 expression in transgenic mice
has yet to be clari®ed. Assembly of an as yet unidenti®ed
endogenous protein (a substitute for p35 that mediates biologic
effects similar to IL-12) with transgenic p40 provides a possible
explanation.
IL-1a and TNF-a are involved in mediating in¯ammatory
skin lesions In the next series of experiments, we wanted to
determine whether transgenic p40 stimulates the synthesis or release
of proin¯ammatory cytokines such as IL-1a and TNF-a in vivo.
Analyzing secretion of these cytokines from cultured keratinocytes,
we found a low baseline secretion of IL-1a and TNF-a from
nontransgenic keratinocytes. In contrast, transgenic keratinocytes
spontaneously secreted higher quantities of both cytokines,
indicating their capability to sustain the ongoing in¯ammation in
K14/p40 mice (Fig 6).
Figure 5. Phenotypic alterations of epidermal cells induced by IL-12 injections are similar to spontaneous changes in K14/p40 mice. (A)
Ear thickening in littermate and K14/p40 mice and (B) FACS analysis of epidermal cells from littermate (left panel) and K14/p40 mice (right panel).
Mice were injected every other day for two consecutive weeks either with recombinant IL-12, p40/40, or vehicle. The increase in ear thickness
relative to the untreated ear was determined on days 0, 2, 4, 6, 8, 10, and 12 and reported as the mean 6 SD. Epidermal cells from littermate and
K14/p40 mice for FACS analysis were obtained on day 12 of the experiment. Phenotypic alterations of epidermal cells upon injections of IL-12 (B.A
and B.B), p40,p40 (B.C and B.D), and vehicle (B.E and B.F). Each experimental group consisted of ®ve female mice with an age of 10 wk. Data are
representative of two experiments.
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Transgenic p40 does not induce IFN-g production by
splenocytes One of the major biologic activities of IL-12 is
the induction of IFN- g from T and natural killer cells. To
determine whether induction of IFN-g secretion is part of the IL-
12-like activity of transgenic p40, we investigated the ability of
transgenic p40 to induce IFN-g secretion by splenocytes and
compared it to IL-12-dependent IFN-g secretion. Whereas
stimulation of splenocytes with IL-12 resulted in a dose-
dependent induction of IFN-g secretion, a rise of IFN-g
production was not seen when K14/p40 keratinocyte-
conditioned medium (containing 50 ng per ml transgenic p40)
was added (Fig 7). To also study a potential antagonistic activity of
transgenic p40, we investigated whether IL-12-induced IFN-g
secretion can be diminished by the addition of transgenic p40. As
determined in titration experiments (data not shown), we found
that recombinant p40/p40, when added at a concentration between
12.5 and 200 ng per ml, completely blocked IL-12 (10, 40, and
200 pg per ml)-mediated IFN-g induction. In contrast to
recombinant p40/40, no inhibitory effect was exerted by the
transgenic product (Fig 7). These results suggest that IFN-g is not a
major factor contributing to the proin¯ammatory activities of
transgenic p40. It thus appears that IL-12 and transgenic p40,
despite exhibiting similar in vivo effects, differ in their in vitro
functions, at least with regard to IFN-g induction.
DISCUSSION
Both IL-12 p70 and p40 have been shown to participate in
pathophysiologic processes relevant to cutaneous in¯ammation
(Junghans et al, 1998; Hong et al, 1999). Whereas IL-12 p70 was
assumed to act as an immunoregulatory cytokine directing T-cell-
speci®c cutaneous immune responses towards a Th1-type response,
the role of p40 is less well de®ned (Trinchieri, 1995; Gately et al,
1998).
We constructed K14/p40 transgenic mice that constitutively
express high levels of IL-12 p40 in basal keratinocytes to investigate
the in vivo role of transgenic p40 secreted in the cutaneous
environment. Transgene mRNA expression of keratinocytes was
con®rmed by northern blotting. Both forms of p40 (p40 and p40/
40) were detected at high levels in media conditioned by transgenic
keratinocytes and in plasma from transgenic mice, suggesting that
transgenic protein is able to cross the basal lamina and enter the
blood system. An important point is that p40 transgenic
keratinocytes do not secrete heterodimeric IL-12. The absence of
this form of IL-12 was con®rmed with an ELISA speci®c for
heterodimeric IL-12 and with a bioassay that measures IL-12-
dependent IFN-g secretion of cultured splenocytes.
For both p40/40 and, to a lesser degree, p40, a function as an IL-
12 antagonist has been demonstrated, and it has been speculated
that p40/40 and p40 are secreted to tightly control IL-12-mediated
immune responses (Gately et al, 1996; Trembleau et al, 1997;
Yoshimoto et al, 1998). For this reason we were surprised to ®nd
an IL-12-like activity of transgenic p40 resulting in a striking
in¯ammatory skin phenotype in p40 transgenic mice. Although the
Figure 6. Spontaneous secretion of IL-1a and TNF-a by cultured
p40 transgenic keratinocytes is enhanced compared to littermate
control keratinocytes. Media conditioned by transgenic and littermate
control keratinocytes were quantitated after 48 h of culture for
immunoreactivity with IL-1a and TNF-a by ELISA. Values are
presented as the mean amount of cytokine (pg per ml) 6 SD of three
keratinocyte cultures.
Figure 7. Transgenic p40 neither induces nor inhibits IFN-g
secretion by splenocytes. Before addition of splenocytes (5 3 105),
96-well culture plates were coated with the non-blocking anti-p40
antibody C15.1 and either recombinant mu IL-12, mu p40/40, or
medium conditioned by K14/p40 and littermate keratinocytes.
Immunoreactive IFN-g secretion was measured after 48 h by ELISA. A
potential antagonistic activity of transgenic p40 was tested by its addition
to IL-12 (10 pg per ml) stimulated cultured splenocytes. Recombinant
murine p40/40 (200 ng per ml) and Sheep7 (1.5 mg per ml), a blocking
antibody to IL-12, completely inhibit IL-12-induced IFN-g secretion.
Data are expressed as mean 6 SD of six replicates per group.
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nature of the proin¯ammatory activity of transgenic p40 is yet
unclear, three possibilities can be entertained to explain this
phenomenon. First, the in¯ammatory response is mediated by
heterodimeric IL-12, but our methods were not sensitive enough
to measure it. Second, p40 and p40/40 have a proin¯ammatory
potential. Third, transgenic p40 combines with an endogenous
protein that substitutes for p35. Although it is conceivable that
transgenic p40 assembles with minute amounts of endogenous p35
to form functional IL-12, our data point against a causative role for
heterodimeric IL-12 in initiating the in¯ammatory response. Using
two methods, an ELISA speci®c for heterodimeric IL-12 and a
bioassay that measures IL-12 function in vitro, we were unable to
detect biologically relevant levels of IL-12 secreted by transgenic
keratinocytes. Because of the extraordinary sensitivity of the IL-12
ELISA and the bioassay, which both go down to 2.5 pg per ml, and
the lack of p35 mRNA expression in murine keratinocytes, it is
very unlikely that biologically relevant amounts of heterodimeric
IL-12 are released in vivo. Our data are in accordance with previous
studies showing that, in contrast to human keratinocytes, murine
keratinocytes do not express p35 mRNA (MuÈller et al, 1994;
Heu¯er et al 1996). In addition, the theoretical possibility of
extracellular pairing of transgenic p40 with dermal p35 is unlikely
to occur as the p35 chain is only secreted as a heterodimer in
association with the p40 chain (Trinchieri, 1995). Secretion of
isolated p35 protein has not been detected in signi®cant amounts
(D'Andrea et al, 1992). We cannot exclude the possibility,
however, that p35 deriving from non-keratinocytes, i.e., neigh-
boring apoptotic Langerhans cells, combines with transgenic p40 in
the extracellular compartment to form heterodimeric IL-12.
The second possible explanation, that p40 or p40/40 are
responsible for the in¯ammatory response in p40 transgenic mice,
is unlikely because these proteins failed to do this in vivo when used
in recombinant form. Although the in vitro functional activity of
recombinant p40 monomer and homodimer was con®rmed by
measuring p40-induced inhibition of IL-12-dependent IFN-g
secretion by splenocytes, we cannot de®nitively exclude the
possibility that, in the injection experiments, we missed the
proin¯ammatory effect by not achieving a suf®ciently high in vivo
concentration. Nevertheless our data are consistent with the
observation that p40 homodimers can function as IL-12 antag-
onists, leading to the hypothesis that p40/40 is produced to limit
IL-12-dependent immunologic reactions (Gately et al, 1996;
Trembleau et al, 1997; Yoshimoto et al, 1998). The reason for
the difference in function between exogenously applied p40
homodimer and monomer and endogenously secreted transgenic
p40 is unclear and merits further investigation. It is possible that a
post-translational modi®cation by keratinocytes, which is not
present in recombinant p40, is necessary to provide IL-12 p40 with
proin¯ammatory potential.
Although we have no de®nitive proof, we favor the third possible
explanation that transgenic p40 assembles with an endogenous
protein that substitutes for p35. A promising candidate is the novel
protein p19, which has recently been described to pair with IL-12
p40 to form IL-23, a T-lymphocyte-activating cytokine (Oppmann
et al, 2000). In transgenic mice, a situation may therefore exist where
agonistic forms of p40, such as IL-23, predominate over antagonistic
variants (P40, p40/p40). Such a constellation would lead to
in¯ammation. The discrepancy between the agonistic predomin-
ance of the transgenic product in vivo and the complete lack of both
IL-12 agonistic and antagonistic in vitro bioactivities is evident.
Potentially, the in vivo and in vitro generated transgenic product
differs in its contents. A situation with a balanced coexistence of
competing IL-12 activities provides a possible explanation for the
results of the in vitro experiments.
Transgenic p40, whatever it is, has remarkable clinical effects
resulting in a cutaneous skin phenotype that corresponds in many
ways to what is seen in eczema, e.g., atopic dermatitis (Cooper,
1994; Leung et al, 1999). The pattern of the in¯ammatory response,
as evidenced by in®ltration of lymphocytes, monocytes, dendritic
cells, mast cells, and eosinophils, as well as focal spongiosis and
epidermal thickening, was similar to cutaneous in¯ammation
induced by injection of recombinant IL-12.
At the present time the expression of IL-12R on resident and
passenger skin cells has not yet been thoroughly investigated. It is
also not clear whether the transgenic product acts in an autocrine or
paracrine fashion. The recent discovery of IL-12R expression and
responsiveness on human melanoma cells and a melanoma cell line
in vitro raises the possibility that, similar to IL-12, the transgenic
product mediates a direct effect on nonhematopoietic cells such as
melanocytes, keratinocytes, and ®broblasts (Yue et al, 1999). In
view of reports about the existence of a membrane-bound form of
heterodimeric IL-12 on macrophages and renal tubular cells, it will
be interesting to see whether a membrane-bound form of
transgenic p40 exists and whether it is responsible for the
phenotype of p40 transgenic mice (Fan et al, 1996, 1997).
P40 transgenic keratinocytes are in an activated state, which
results in surface expression of MHC class II and intercellular
adhesion molecule 1 (ICAM-1) and spontaneous secretion of the
proin¯ammatory cytokines IL-1a and TNF-a. There is abundant
evidence suggesting an important role for IL-1a and TNF-a in
initiating skin in¯ammation (Enk and Katz, 1992; Cheng et al,
1992; Groves et al, 1995; Kupper and Groves, 1995). In this
context, it remains to be elucidated whether in p40 transgenic mice
the induction of MHC class II and ICAM-1 is mediated directly by
transgenic p40 or indirectly by other proin¯ammatory cytokines
induced by the transgenic product. The fact that both IL-1a and
TNF-a are spontaneously released by transgenic keratinocytes
in vitro supports the involvement of indirect effects in triggering the
in¯ammatory cascade.
P40 transgenic mice have increased numbers of epidermal
Langerhans cells and dermal dendritic cells. Whether this results
from an increased in¯ux of precursor cells, decreased ef¯ux to
lymph nodes, or reduced apoptosis is currently under investigation.
Interestingly, IL-4 transgenic mice also exhibit a bigger compart-
ment of epidermal Langerhans cells (Elbe-BuÈrger et al, 1999). In
contrast to p40 and IL-4 transgenic mice, there is a depletion of
epidermal Langerhans cells in IFN-g-expressing mice, probably
because of induction of their migration into the lymph nodes
(Carroll et al, 1996). The increased number of Langerhans cells and
dermal dendritic cells in p40 transgenic mice can be either a direct
effect of p40 on dendritic cells or induced by the altered cytokine
milieu (Kelleher and Knight, 1998). Elevated IL-1a levels alone are
unlikely to mediate this effect as the number of Langerhans cells is
unaltered in IL-1a transgenic mice (Groves et al, 1995). Similarly,
we do not believe that TNF-a plays an important role. In fact, this
cytokine increases the migratory potency of Langerhans cells,
resulting in their accumulation in lymph nodes (Kimber and
Cumberbatch, 1992; Wang et al, 1996; Cumberbatch et al, 1997).
In contrast to IL-12, IFN-g does not appear to be an important
mediator of the proin¯ammatory activities of transgenic p40. From
our in vitro experiments it is clear that direct induction of IFN-g by
the transgenic product does not occur. A possible indirect
induction of IFN-g in vivo, however, cannot be excluded by
these experiments. A powerful way to examine this would be the
crossing of IFN-g ±/± with p40 transgenic mice.
In summary, our data provide ®rst evidence that keratinocyte-
derived transgenic p40 is able to initiate cutaneous in¯ammation.
The fact that skin in¯ammation in p40 transgenic mice strongly
resembles the skin phenotype induced by injections of recombinant
IL-12 supports the idea that heterodimeric IL-12 and transgenic
p40 exert similar in vivo functions. Studies are in progress to
establish the contribution of transgenic p40 to immunity. Should it
turn out that transgenic p40 is able to polarize T helper immune
responses similar to IL-12, it will be a promising new target to
modulate immune responses.
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